Loading…
Company plans to expand the trial with additional arms.
Immuneering Corporation announced on 2025-01-07 Immuneering Corporation announced positive data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of IMM-1-104, and plans to expand the trial with additional arms.
The announcement cited ORR = 43%, DCR = 86%, ORR of 23%, DCR of 48%, 18.6% ORR, 67% reduction (PR), and 100% reduction (PR).
Immuneering Corporation Class A Common Stock has a free float of 45,260,300 shares and 64,570,000 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.